Recognizing Photoallergy, Phototox HS: New Insights Into Disease Mechanism And An Evolving Treatment Landscape

Hidradenitis suppurativa is a chronic incapacitating and debilitating inflammatory disease with a significant unmet medical need. Current treatment modalities encompass topical medications; systemic therapies such as repeated and/or rotational courses of systemic antibiotics, retinoids and hormonal treatment, as well as various surgical interventions. Despite the incomplete understanding of its pathophysiology, the involvement of multiple cytokines, particularly the TNF-α and IL-17 pathways, plays a pivotal role.
HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged and agents targeting the IL-17 and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways are the most advanced in phase III clinical trials. In this session, we will delve into the novel and emerging therapeutics for HS.